Structure-Based Development of Small Molecule PFKFB3 Inhibitors: A Framework for Potential Cancer Therapeutic Agents Targeting the Warburg Effect
2011

Developing Small Molecule Inhibitors for Cancer Treatment

publication Evidence: moderate

Author Information

Author(s): Seo Minsuh, Kim Jeong-Do, Neau David, Sehgal Inder, Lee Yong-Hwan

Primary Institution: Louisiana State University

Hypothesis

Inhibition of PFKFB3 can suppress glycolysis in cancer cells and lead to cell death.

Conclusion

The study identifies N4A and YN1 as potent inhibitors of PFKFB3, which effectively reduce glycolysis and inhibit cancer cell growth.

Supporting Evidence

  • N4A and YN1 were shown to inhibit PFKFB3 activity effectively.
  • Both inhibitors led to a significant reduction in Fru-2,6-BP levels in cancer cells.
  • N4A and YN1 caused substantial cell death in HeLa cells.
  • YN1 demonstrated a 5-fold increase in potency compared to the initial lead compound N4A.
  • Cell growth inhibition assays confirmed the effectiveness of the inhibitors on cancer cell proliferation.

Takeaway

Scientists found a way to stop cancer cells from getting energy by blocking a specific protein, which makes the cancer cells die.

Methodology

The study involved identifying and testing small molecule inhibitors of PFKFB3 through structural analysis and cell culture experiments.

Limitations

The study primarily focuses on in vitro results, and further in vivo studies are needed to confirm the therapeutic potential.

Digital Object Identifier (DOI)

10.1371/journal.pone.0024179

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication